Return to Publications
October 2017
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.
Coral Omene, MD, PhD

Awareness of Cognitive Impairments from Breast Cancer Treatment

Research shows that up to 75 percent of women experience deficits in their intellectual capacity (i.e., cognitive impairment) during or after breast cancer treatment including being "forgetful" and having "trouble concentrating or remembering." Coral Omene MD, PhD, who is a medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, shares more about the need to address these issues so that quality of life for the patient is maintained.


Exploring Immunotherapy for Carcinoid and Pancreatic Neuroendocrine Tumors

A clinical trial testing the immunotherapy drug pembrolizumab shows it to be well tolerated among patients who have carcinoid or pancreatic neuroendocrine tumors. Immunotherapy drugs put the body's natural defenses back to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells. Janice M. Mehnert, MD, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey and associate professor of medicine at Rutgers Robert Wood Johnson Medical School, is the lead author of research presented at the European Society for Medical Oncology 2017 Congress in Spain last month.

Hu and Feng

Targeting a Binding Protein in Mutated p53 Could Yield New Cancer Treatment Strategies

The targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer carries mutations in the p53 gene, according to findings by Rutgers Cancer Institute of New Jersey investigators. The work explores the mechanism by which mutant p53 exhibits oncogenic activities that promote tumor progression. Wenwei Hu, PhD, and Zhaohui Feng, MD, PhD, who are resident research members at Rutgers Cancer Institute and associate professors of radiation oncology at Rutgers Robert Wood Johnson Medical School, are the senior authors of the work published in the September 22 online issue of Genes & Development.

check your neck

Check Your Neck!

There are approximately 57,000 newly diagnosed thyroid cancers annually in the U.S., with papillary thyroid cancer being the most common. The butterfly-shaped thyroid gland in the lower neck makes a hormone that plays a role in cell metabolism. While thyroid cancers are common, they may have few or no signs or symptoms and often are found during medical tests for other conditions. Section Chief of Endocrine Surgery at Rutgers Cancer Institute of New Jersey Amanda M. Laird, MD, FACS, who is also an associate professor of surgery at Rutgers Robert Wood Johnson Medical School, says know the signs, symptoms and risk factors.